Remediation of Age-related Cognitive Decline: Vortioxetine & Cognitive

Status Completed

Clinical Trial Summary

Clinical Trial Description

The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive training versus placebo plus cognitive training.

Vortioxetine is considered investigational when used as a treatment for age-related cognitive decline, which means that it has not been approved by the U.S. Food and Drug Administration for this purpose. Vortioxetine is approved by the U.S. Food and Drug Administration as a treatment for depression, and also goes by the name Trintellix (formerly known as Brintellix). That means that, while the drug itself is approved by the FDA, it is not approved for the reasons the investigators are using it in this study.

Participation in this study entails an estimated 6 study visits over the course of approximately six months. Participants will complete various assessments at our lab at the Washington University School of Medicine along with check-in visits in-person or over the phone. Additionally, they will participate in at home computerized cognitive training for approximately six months, supplemented with either vortioxetine or placebo.

The investigators will assess memory and problem-solving abilities using paper and pencil, computerized measures, and self-assessments of how participants feel. These tests could include numbers, letters, symbols, words, or sentences. These tests will be repeated throughout the study. If eligible to do so, participants will complete a baseline MRI scan.

A subset of participants who completed a baseline MRI scan will complete another MRI scan after approximately 26 weeks of vortioxetine or placebo and at home computerized cognitive training. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03272711
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Completed
Phase	Phase 4
Start date	August 31, 2016
Completion date	January 24, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04121728` - Modulation of Attention in Event Related Potential (ERPs) as a Marker of Early Cognitive Decline by Ginkgo Biloba	N/A
Enrolling by invitation	`NCT04641663` - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)	N/A
Completed	`NCT03228446` - The Effects of Attentional Filter Training on Working Memory	N/A
Completed	`NCT04910399` - Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging	N/A
Recruiting	`NCT03275363` - The University of Hong Kong Neurocognitive Disorder Cohort	N/A
Completed	`NCT02185222` - Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint	Phase 3
Completed	`NCT03162913` - The Effects of Strawberry Supplementation on Memory and Gait Among Over-weight Older Adults	N/A
Completed	`NCT02416401` - Attention Training for Learning Enhancement and Resilience Trial	N/A
Completed	`NCT02922920` - Effects of Tart Cherry Juice on the Body	N/A
Completed	`NCT01120860` - Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance	N/A
Recruiting	`NCT03702335` - Impact of Comprehensive Dietary Counseling on Dietary Quality, Mental Health, and Quality of Life in Older Adults	N/A
Completed	`NCT05828043` - Brain Aging: Muscle-to-brain Axis Modulates Physio-cognitive Decline	N/A
Active, not recruiting	`NCT05348694` - OsteoPreP: Food Supplements for Postmenopausal Bone Health	Phase 4
Recruiting	`NCT05194787` - TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease
Recruiting	`NCT04184375` - Cognitive Stimulation for Elderly Bipolar Patients	N/A
Recruiting	`NCT04171323` - The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia	N/A
Not yet recruiting	`NCT06248723` - ItaliaN Study With Tailored Multidomain Interventions to Prevent Functional and Cognitive Decline in Community-dwelling Older Adults	N/A
Terminated	`NCT04732312` - Impact of Formal Home Help on Quality of Life for Caregivers of Elderly Patients With Neurocognitive Impairment
Recruiting	`NCT06377254` - Multi-organ Responses to CHronic Physical Activity and INactivity	N/A
Not yet recruiting	`NCT04566757` - Safety and Efficacy of Human Umbilical Cord Blood Plasma Infusion for Age-Related Cognitive Decline	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training — BBS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms